Innate Pharma (IPHA) Non-Current Assets (2017 - 2025)

Innate Pharma (IPHA) has 9 years of Non-Current Assets data on file, last reported at $18.6 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Assets fell 31.12% year-over-year to $18.6 million; the trailing twelve-month figure through Dec 2025 stood at $18.6 million (down 31.12% YoY), and the FY2025 full-year result was $18.6 million, down 31.12% from the prior year.
• Non-Current Assets for Q4 2025 stood at $18.6 million, down from $31.6 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $164.4 million in Q2 2021 and bottomed at $18.6 million in Q4 2025.
• The 5-year median for Non-Current Assets is $51.2 million (2023), against an average of $69.8 million.
• Peak annual rise in Non-Current Assets reached 7.44% in 2021, while the deepest fall reached 99.9% in 2021.
• A 5-year view of Non-Current Assets shows it stood at $147.8 million in 2021, then sank by 58.97% to $60.7 million in 2022, then sank by 51.81% to $29.2 million in 2023, then retreated by 7.47% to $27.1 million in 2024, then tumbled by 31.12% to $18.6 million in 2025.
• The last three Non-Current Assets figures came in at $18.6 million (Q4 2025), $31.6 million (Q2 2025), and $27.1 million (Q4 2024), per Business Quant data.

Peer Comparison